{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:23:15Z","timestamp":1790734995927,"version":"4.1.0"},"reference-count":24,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,10,7]],"date-time":"2008-10-07T00:00:00Z","timestamp":1223337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vet Pharm &amp; Therapeutics"],"published-print":{"date-parts":[[2009,6]]},"abstract":"<jats:p>The aim of the current study was to investigate whether multiple oral dosing of valacyclovir could result in plasma concentrations exceeding the EC<jats:sub>50<\/jats:sub>\u2010value of acyclovir against equine herpesvirus 1 (EHV1) during the majority of the treatment period. Additionally, we wanted to determine the concentration of acyclovir in nasal mucus and cerebrospinal fluid (CSF). Valacyclovir was administered to four horses and two ponies, three times daily, at a dosage of 40\u2003mg\/kg, for four consecutive days. Blood was collected prior to each administration and 1\u2003h after dosing. Nasal mucus samples and CSF were collected once during treatment; 1\u2003h after the last administration. This dosage regimen resulted in plasma concentrations that were higher than the EC<jats:sub>50<\/jats:sub>\u2010value of 1.7\u2003\u03bcg\/mL, i.e. EC<jats:sub>50<\/jats:sub>of an isolate highly susceptible to acyclovir, for 80% of the treatment period; and higher than the EC<jats:sub>50<\/jats:sub>\u2010value of 3.0\u2003\u03bcg\/mL, i.e. EC<jats:sub>50<\/jats:sub>of an isolate less susceptible to acyclovir, for 60% of the treatment period. Concentration in nasal mucus samples and CSF was 0.36\u20131.17\u2003\u03bcg\/mL and 0.11\u20130.23\u2003\u03bcg\/mL, respectively. This study illustrates that multiple dosing of valacyclovir may result in a therapeutic benefit as plasma concentrations could be maintained above the EC<jats:sub>50<\/jats:sub>\u2010value of acyclovir against EHV1 for more than 50% of the treatment period. Acyclovir could be detected in both nasal mucus samples and CSF. However, these concentrations were lower than the EC<jats:sub>50<\/jats:sub>.<\/jats:p>","DOI":"10.1111\/j.1365-2885.2008.01025.x","type":"journal-article","created":{"date-parts":[[2008,10,7]],"date-time":"2008-10-07T07:13:20Z","timestamp":1223363600000},"page":"207-212","source":"Crossref","is-referenced-by-count":23,"title":["Multiple oral dosing of valacyclovir in horses and ponies"],"prefix":"10.1111","volume":"32","author":[{"given":"B.","family":"GARR\u00c9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"BAERT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"NAUWYNCK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"DEPREZ","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"DE BACKER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"CROUBELS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,5,19]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"78","article-title":"Molecular epizootiology, pathogenesis and prophylaxis of equine herpesvirus\u20101 infections","volume":"2","author":"Allen G.P.","year":"1986","journal-title":"Progress in Veterinary Microbiology and Immunology"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2006.tb02901.x"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(82)90088-2"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4613-1587-2_6"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1354\/vp.38-4-474"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-107-6-859"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/106002808501900703"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2000.tb02236.x"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2007.01.004"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00116-07"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1939-1676.2007.tb02942.x"},{"key":"e_1_2_6_13_1","volume-title":"Development of a Taste\u2010Masked Quinine Pamoate Suspension","author":"Huyghebaert N.K.","year":"2007"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-3306.2001.tb00600.x"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh244"},{"key":"e_1_2_6_16_1","article-title":"Determination of acyclovir in horse plasma and body fluids by high\u2010performance liquid chromatography combined with fluorescence detection and heated electrospray ionization tandem mass spectrometry","author":"Maes A.","year":"2008","journal-title":"Biomedical Chromatography"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/vr.136.1.7"},{"key":"e_1_2_6_18_1","doi-asserted-by":"crossref","first-page":"366","DOI":"10.21825\/vdt.89249","article-title":"A local epidemic of equine herpesvirus 1\u2010induced neurological disorders in Belgium","volume":"72","author":"Van Der Meulen K.M.","year":"2003","journal-title":"Vlaams Diergeneeskundig Tijdschrift"},{"key":"e_1_2_6_19_1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0022-3565(25)32802-8","article-title":"The disposition of acyclovir in different species","volume":"219","author":"De Miranda P.","year":"1981","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"e_1_2_6_20_1","first-page":"367","volume-title":"Clinical Pharmacokinetics: Concepts and Applications","author":"Rowland M.","year":"1995"},{"key":"e_1_2_6_21_1","first-page":"353","volume-title":"Applied Biopharmaceutics and Pharmacokinetics","author":"Shargel L.","year":"1993"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1439-0450.2002.00537.x"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.1.150-157.2001"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2885.2004.00600.x"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-4431.2005.00145.x"}],"container-title":["Journal of Veterinary Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2885.2008.01025.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2885.2008.01025.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T13:31:53Z","timestamp":1738416713000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2885.2008.01025.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,19]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["10.1111\/j.1365-2885.2008.01025.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2885.2008.01025.x","archive":["Portico"],"relation":{},"ISSN":["0140-7783","1365-2885"],"issn-type":[{"value":"0140-7783","type":"print"},{"value":"1365-2885","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,19]]}}}